Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib + nivolumab in ALK-positive non-small cell lung cancer
NL-OMON44906Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ceritinib and nivolumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Novartis. Primary endpoints: Dose-limiting toxicity and Objective response rate. Started Oct 2015; status: active, not recruiting.
02
Drugs
ceritinibnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44906.